Show simple item record

dc.contributor.authorGudmundsdottir, V
dc.contributor.authorPedersen, HK
dc.contributor.authorMazzoni, G
dc.contributor.authorAllin, KH
dc.contributor.authorArtati, A
dc.contributor.authorBeulens, JW
dc.contributor.authorBanasik, K
dc.contributor.authorBrorsson, C
dc.contributor.authorCederberg, H
dc.contributor.authorChabanova, E
dc.contributor.authorDe Masi, F
dc.contributor.authorElders, PJ
dc.contributor.authorForgie, I
dc.contributor.authorGiordano, GN
dc.contributor.authorGrallert, H
dc.contributor.authorGupta, R
dc.contributor.authorHaid, M
dc.contributor.authorHansen, T
dc.contributor.authorHansen, TH
dc.contributor.authorHattersley, AT
dc.contributor.authorHeggie, A
dc.contributor.authorHong, MG
dc.contributor.authorJones, AG
dc.contributor.authorKoivula, R
dc.contributor.authorKokkola, T
dc.contributor.authorLaakso, M
dc.contributor.authorLøngreen, P
dc.contributor.authorMahajan, A
dc.contributor.authorMari, A
dc.contributor.authorMcDonald, TJ
dc.contributor.authorMcEvoy, D
dc.contributor.authorMusholt, PB
dc.contributor.authorPavo, I
dc.contributor.authorPrehn, C
dc.contributor.authorRuetten, H
dc.contributor.authorRidderstråle, M
dc.contributor.authorRutters, F
dc.contributor.authorSharma, S
dc.contributor.authorSlieker, RC
dc.contributor.authorSyed, A
dc.contributor.authorTajes, JF
dc.contributor.authorThomas, CE
dc.contributor.authorThomsen, HS
dc.contributor.authorVangipurapu, J
dc.contributor.authorVestergaard, H
dc.contributor.authorViñuela, A
dc.contributor.authorWesolowska-Andersen, A
dc.contributor.authorWalker, M
dc.contributor.authorAdamski, J
dc.contributor.authorSchwenk, JM
dc.contributor.authorMcCarthy, MI
dc.contributor.authorPearson, E
dc.contributor.authorDermitzakis, E
dc.contributor.authorFranks, PW
dc.contributor.authorPedersen, O
dc.contributor.authorBrunak, S
dc.date.accessioned2021-05-12T15:42:20Z
dc.date.issued2020-12-01
dc.description.abstractBackground: The rising prevalence of type 2 diabetes (T2D) poses a major global challenge. It remains unresolved to what extent transcriptomic signatures of metabolic dysregulation and T2D can be observed in easily accessible tissues such as blood. Additionally, large-scale human studies are required to further our understanding of the putative inflammatory component of insulin resistance and T2D. Here we used transcriptomics data from individuals with (n = 789) and without (n = 2127) T2D from the IMI-DIRECT cohorts to describe the co-expression structure of whole blood that mainly reflects processes and cell types of the immune system, and how it relates to metabolically relevant clinical traits and T2D. Methods: Clusters of co-expressed genes were identified in the non-diabetic IMI-DIRECT cohort and evaluated with regard to stability, as well as preservation and rewiring in the cohort of individuals with T2D. We performed functional and immune cell signature enrichment analyses, and a genome-wide association study to describe the genetic regulation of the modules. Phenotypic and trans-omics associations of the transcriptomic modules were investigated across both IMI-DIRECT cohorts. Results: We identified 55 whole blood co-expression modules, some of which clustered in larger super-modules. We identified a large number of associations between these transcriptomic modules and measures of insulin action and glucose tolerance. Some of the metabolically linked modules reflect neutrophil-lymphocyte ratio in blood while others are independent of white blood cell estimates, including a module of genes encoding neutrophil granule proteins with antibacterial properties for which the strongest associations with clinical traits and T2D status were observed. Through the integration of genetic and multi-omics data, we provide a holistic view of the regulation and molecular context of whole blood transcriptomic modules. We furthermore identified an overlap between genetic signals for T2D and co-expression modules involved in type II interferon signaling. Conclusions: Our results offer a large-scale map of whole blood transcriptomic modules in the context of metabolic disease and point to novel biological candidates for future studies related to T2D.en_GB
dc.description.sponsorshipInnovative Medicines Initiative Joint Undertakingen_GB
dc.description.sponsorshipEuropean Union FP7en_GB
dc.description.sponsorshipNovo Nordisk Foundationen_GB
dc.description.sponsorshipNational Institute for Health Research (NIHR)en_GB
dc.description.sponsorshipWellcome Trusten_GB
dc.description.sponsorshipNIHen_GB
dc.description.sponsorshipEuropean Research Council (ERC)en_GB
dc.identifier.citationVol. 12, article 109en_GB
dc.identifier.doi10.1186/s13073-020-00806-6
dc.identifier.grantnumber115317en_GB
dc.identifier.grantnumberFP7/2007–2013en_GB
dc.identifier.grantnumberNNF17OC0027594en_GB
dc.identifier.grantnumber17/0005624en_GB
dc.identifier.grantnumber090532en_GB
dc.identifier.grantnumberU01-DK105535en_GB
dc.identifier.grantnumberCoG2015_681742_NASCENTen_GB
dc.identifier.grantnumberNNF14CC0001
dc.identifier.grantnumberNNF18OC0031650
dc.identifier.grantnumber098381
dc.identifier.grantnumber106130
dc.identifier.grantnumber203141
dc.identifier.grantnumber212259
dc.identifier.urihttp://hdl.handle.net/10871/125655
dc.language.isoenen_GB
dc.publisherBMCen_GB
dc.rights© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.en_GB
dc.subjectType 2 diabetesen_GB
dc.subjectTranscriptomicsen_GB
dc.subjectCo-expression modulesen_GB
dc.subjectOmics data integrationen_GB
dc.titleWhole blood co-expression modules associate with metabolic traits and type 2 diabetes: an IMI-DIRECT studyen_GB
dc.typeArticleen_GB
dc.date.available2021-05-12T15:42:20Z
dc.identifier.issn1756-994X
dc.descriptionThis is the final version. Available on open access from BMC via the DOI in this record. en_GB
dc.descriptionAvailability of data and materials Due to the type of consent provided by study participants and the ethical approvals for this study, individual-level clinical and omics data from IMI-DIRECT cohorts cannot be transferred from the centralized IMI-DIRECT repository. Requests for access to IMI-DIRECT data, including data presented here, can be made to DIRECTdataaccess@Dundee.ac.uk. Requestors will be provided with information and assistance on how data can be accessed via the DIRECT Computerome secure analysis platform following submission of appropriate documentation. The IMI-DIRECT data access policy is available from www.direct-diabetes.org.en_GB
dc.identifier.journalGenome Medicineen_GB
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/en_GB
dcterms.dateAccepted2020-11-11
rioxxterms.versionVoRen_GB
rioxxterms.licenseref.startdate2020-12-01
rioxxterms.typeJournal Article/Reviewen_GB
refterms.dateFCD2021-05-12T15:27:17Z
refterms.versionFCDVoR
refterms.dateFOA2021-05-12T15:42:56Z
refterms.panelAen_GB


Files in this item

This item appears in the following Collection(s)

Show simple item record

© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
Except where otherwise noted, this item's licence is described as © The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.